Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News SCAI 2025

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

L.A. McKeown

May 02, 2025

News Conference News TVT 2023

Five-Year Follow-up Reassures on Severe Patient-Prosthesis Mismatch in TAVI

Shelley Wood

June 14, 2023

News Opinion CV Team Dispatch

December 2022 News Roundup

L.A. McKeown

December 28, 2022

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

News Conference News AHA 2019

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Yael L. Maxwell

November 18, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

NOTION and UK TAVI Report Good Long-term Function of Transcatheter Aortic Valves

L.A. McKeown

February 06, 2019

News Daily News

Is There a Volume-Outcome Relationship With Newer TAVR Valves? Maybe Not, Registry Suggests

Todd Neale

January 30, 2019

News Daily News

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Michael O'Riordan

September 12, 2018

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

Advertisement

More Patient-Prosthesis Mismatch With TAVI in Women, but 5-Year Survival Unaffected

Five-Year Follow-up Reassures on Severe Patient-Prosthesis Mismatch in TAVI

December 2022 News Roundup

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

FDA Expands TAVR Indication to Low-Risk Patients

NOTION and UK TAVI Report Good Long-term Function of Transcatheter Aortic Valves

Is There a Volume-Outcome Relationship With Newer TAVR Valves? Maybe Not, Registry Suggests

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TCTMD’s Top 10 Most Popular Stories for August 2016

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

TCTMD’s Top 10 Most Popular Stories for April 2016

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content